BiosimilarBiological

CT-P10 clinical trials

A product of Rituximab; its studies count on that page too.

studies test it: 3
open now: 0
in phase 3: 3
first study started: 2014

How each study uses CT-P10 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States: 26 Nov 1997 · RITUXAN · BLA 103705 (FDA, Drugs@FDA; as Rituximab)
European Union: 2 Jun 1998 · MabThera · EMEA/H/C/000165 (EMA; as Rituximab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

CT-P10: 3
rituximab: 2

Studies by the year they started

3 studies that test it; most in 2014 (2)

Studies that test CT-P10, by start year
Year	Studies
2014	2
2015	1

By phase

A phase 1/2 study counts in both.

Phase 3: 3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, Follicular: 2
Arthritis, Rheumatoid: 1

Who runs them

Industry 3 · Other 0

Celltrion (3)

Related medicines

As reviewed, each with the page that says it.

A biosimilar of Rituximab

Studies

Open first, then newest update. How each study uses CT-P10 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.